share_log

Cantor Fitzgerald Reiterates Overweight on Xenon Pharmaceuticals, Maintains $65 Price Target

Benzinga ·  Aug 9 11:14  · Ratings

Cantor Fitzgerald analyst Josh Schimmer reiterates Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and maintains $65 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment